Alexander Shoushtari
Memorial Sloan Kettering Cancer Center · Alliance for Clinical Trials in Oncology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alexander Shoushtari as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:41 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05640193 · A Study of LN-144 in People With Metastatic Melanoma to the BrainMemorial Sloan Kettering Cancer Center · active not recruiting · Metastatic Melanoma · principal investigator
- Ph2NCT05384496 · Axitinib and Nivolumab for the Treatment of Mucosal MelanomaMemorial Sloan Kettering Cancer Center · recruiting · Mucosal Melanoma · principal investigator
- Ph1NCT03922880 · Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal MelanomaMemorial Sloan Kettering Cancer Center · completed · Uveal Melanoma · principal investigator
- Ph2NCT03420508 · Treating Patients With Melanoma and ALK Alterations With EnsartinibMemorial Sloan Kettering Cancer Center · active not recruiting · Melanoma · principal investigator
- Ph2NCT03220009 · Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal MelanomaNational Cancer Institute (NCI) · withdrawn · Cervical Carcinoma, Esophageal Carcinoma, Mucosal Melanoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:41 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Alliance for Clinical Trials in Oncology Member Site CoreU10CA180821 · NCI · ALLIANCE NCTN FOUNDATION · PI Evanthia Galanis · fiscal years 2014 to 2026Named on NCT03220009
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:41 UTC. The ranking covers the 200 most relevant of 26 PubMed records, and a shared surname and initials can bring in a namesake. All 26 on PubMed
- Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.N Engl J Med · 2021769 citationsRCR 39.3
- 297 citationsRCR 17.4
- Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.N Engl J Med · 2023264 citationsRCR 22.2
- Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma.Clin Cancer Res · 2020223 citationsRCR 8.8
- Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).J Clin Oncol · 2018218 citationsRCR 7.5
- Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial.Nat Med · 2022150 citationsRCR 9.7
- Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma.JAMA Oncol · 2018126 citationsRCR 3.9
- Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab.Clin Cancer Res · 2017112 citationsRCR 3.2
- Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071.Mol Cancer Ther · 202055 citationsRCR 2.6
- Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses.J Immunother Cancer · 202244 citationsRCR 2.4